Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595036 | 1.00 | ADRA1D (0.44) | ADRA1DCYP4F2CYP4A11L3MBTL1PTGDR2 | |
| SCHEMBL5757459 | 0.92 | ADRA1D (0.43) | ADRA1DCYP4F2CYP4A11L3MBTL1PTGDR2 | |
| SCHEMBL27624382 | 0.86 | ADRA1D (0.42) | ADRA1DL3MBTL1PTGDR2CCR2CA1 | |
| SCHEMBL1015882 | 0.85 | GSTO1 (0.44) | CYP4F2CYP4A11L3MBTL1CCR2GSTO1 | |
| SCHEMBL1597797 | 0.83 | TRPV4 (0.49) | ADRA1DCYP4F2CYP4A11CA1CA2 | |
| SCHEMBL13211313 | 0.83 | ADRA1D (0.45) | ADRA1DL3MBTL1PTGDR2CCR2CA1 | |
| SCHEMBL24051716 | 0.81 | CA1 (0.44) | CYP4F2CYP4A11L3MBTL1CA1CA2 | |
| SCHEMBL6196958 | 0.81 | ADRA1D (0.47) | ADRA1DPTGDR2CCR2CA1CA2 | |
| SCHEMBL5756302 | 0.81 | L3MBTL1 (0.55) | CYP4F2CYP4A11L3MBTL1CA1CA2 | |
| SCHEMBL20488770 | 0.81 | GSTO1 (0.51) | CYP4F2CYP4A11GSTO1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717734-B2 | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof | PHARMAXIS LTD. (AU) | 2020-07-21 | — | — | US | disclosed |
| US-20190119269-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2019-04-25 | — | — | US | disclosed |
| CN-109153642-A | Indoles and azaindole halogenated allylamine derivatives inhibitors of lysyloxidase and application thereof | 法玛西斯有限公司 | 2019-01-04 | — | — | CN | disclosed |
| EP-3414226-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | Pharmaxis Ltd. (AU) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017136871-A9 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2018-02-15 | — | — | WO | disclosed |
| WO-2017136871-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017136871-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2017-08-17 | — | — | WO | disclosed |
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| EP-2089384-B1 | 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-2271624-B9 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-20080146595-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| EP-1761529-B1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007068418-A1 | USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| EP-1761529-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
| WO-2005123731-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| EP-1562902-A1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004043924-A1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | CCR1, CCL2, CCL11 | ADRA1D 152/4885CYP4F2 4308/4885CYP4A11 2642/4885 |
| US-20080146595-A1 | Non-nucleoside reverse transcriptase inhibitors | NQO2, SAMHD1, POLR2A | ADRA1D 1477/4885CYP4F2 3046/4885CYP4A11 1701/4885 |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ADRA1D 615/4885CYP4F2 799/4885CYP4A11 1212/4885 |
| US-10717734-B2 | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof | IDO1, IDO2, INMT | ADRA1D 367/4885CYP4F2 706/4885CYP4A11 1241/4885 |
| US-20190119269-A1 | INDOLE AND AZAINDOLE HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | ADRA1D 367/4885CYP4F2 706/4885CYP4A11 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.